Collegium Pharmaceutical (NASDAQ:COLL) Trading Up 7.7% Following Analyst Upgrade

Collegium Pharmaceutical Inc (NASDAQ:COLL) traded up 7.7% during trading on Friday after SunTrust Banks raised their price target on the stock to $22.00. SunTrust Banks currently has a buy rating on the stock. Collegium Pharmaceutical traded as high as $19.97 and last traded at $19.39, 50,124 shares traded hands during trading. A decline of 88% from the average session volume of 405,868 shares. The stock had previously closed at $18.00.

Several other analysts have also issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $24.00 price objective (down from $35.00) on shares of Collegium Pharmaceutical in a report on Thursday, August 8th. ValuEngine upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Jefferies Financial Group boosted their price objective on shares of Collegium Pharmaceutical from $26.00 to $36.00 in a report on Thursday. BidaskClub upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Needham & Company LLC reduced their price objective on shares of Collegium Pharmaceutical from $33.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $24.57.

In related news, Director David Hirsch sold 22,106 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $11.65, for a total value of $257,534.90. Following the sale, the director now directly owns 64,223 shares in the company, valued at approximately $748,197.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.08% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC increased its stake in Collegium Pharmaceutical by 19.1% during the second quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock worth $56,855,000 after purchasing an additional 693,812 shares during the period. BlackRock Inc. increased its stake in Collegium Pharmaceutical by 7.1% during the second quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock worth $32,724,000 after purchasing an additional 165,018 shares during the period. Vanguard Group Inc. increased its stake in Collegium Pharmaceutical by 1.5% during the second quarter. Vanguard Group Inc. now owns 1,571,474 shares of the specialty pharmaceutical company’s stock worth $20,665,000 after purchasing an additional 22,883 shares during the period. Rice Hall James & Associates LLC increased its stake in Collegium Pharmaceutical by 5.8% during the second quarter. Rice Hall James & Associates LLC now owns 1,260,690 shares of the specialty pharmaceutical company’s stock worth $16,578,000 after purchasing an additional 69,549 shares during the period. Finally, Cortina Asset Management LLC increased its stake in Collegium Pharmaceutical by 81.0% during the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock worth $6,703,000 after purchasing an additional 228,035 shares during the period. Hedge funds and other institutional investors own 92.17% of the company’s stock.

The company has a debt-to-equity ratio of 0.23, a current ratio of 1.25 and a quick ratio of 1.20. The company has a market capitalization of $459.95 million, a PE ratio of -16.12 and a beta of 0.52. The stock’s 50 day simple moving average is $12.01 and its 200-day simple moving average is $12.05.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The company had revenue of $72.94 million for the quarter, compared to analyst estimates of $74.32 million. During the same period in the prior year, the firm posted ($0.50) earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. On average, equities analysts predict that Collegium Pharmaceutical Inc will post -0.51 earnings per share for the current year.

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Article: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.